Production and immunogenicity of chimeric virus-like particles containing the spike glycoprotein of infectious bronchitis virus.
10.4142/jvs.2014.15.2.209
- Author:
Lishan LV
1
;
Xiaoming LI
;
Genmei LIU
;
Ran LI
;
Qiliang LIU
;
Huifang SHEN
;
Wei WANG
;
Chunyi XUE
;
Yongchang CAO
Author Information
1. State Key Laboratory of Biocontrol, School of Life Sciences, Sun Yat-sen University, Guangzhou 510006, China. caoych@mail.sysu.edu.cn
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
chimeric virus-like particle;
immune response;
infectious bronchitis virus
- MeSH:
Animals;
Antibodies, Viral/blood;
*Chickens;
Chimera/genetics/immunology;
Coronavirus Infections/prevention & control/*veterinary/virology;
Female;
*Immunity, Innate;
Infectious bronchitis virus/genetics/*immunology;
Influenza A Virus, H5N1 Subtype/genetics/immunology;
Injections, Intramuscular/veterinary;
Mice;
Mice, Inbred BALB C;
Neuraminidase/genetics;
Poultry Diseases/*prevention & control/virology;
Recombinant Fusion Proteins/genetics/immunology;
Spike Glycoprotein, Coronavirus/genetics/*immunology;
Vaccines, Synthetic/administration & dosage/genetics/immunology;
Vaccines, Virus-Like Particle/administration & dosage/genetics/*immunology;
Viral Proteins/genetics
- From:Journal of Veterinary Science
2014;15(2):209-216
- CountryRepublic of Korea
- Language:English
-
Abstract:
Infectious bronchitis virus (IBV) poses a severe threat to the poultry industry and causes heavy economic losses worldwide. Vaccination is the most effective method of preventing infection and controlling the spread of IBV, but currently available inactivated and attenuated virus vaccines have some disadvantages. We developed a chimeric virus-like particle (VLP)-based candidate vaccine for IBV protection. The chimeric VLP was composed of matrix 1 protein from avian influenza H5N1 virus and a fusion protein neuraminidase (NA)/spike 1 (S1) that was generated by fusing IBV S1 protein to the cytoplasmic and transmembrane domains of NA protein of avian influenza H5N1 virus. The chimeric VLPs elicited significantly higher S1-specific antibody responses in intramuscularly immunized mice and chickens than inactivated IBV viruses. Furthermore, the chimeric VLPs induced significantly higher neutralization antibody levels than inactivated H120 virus in SPF chickens. Finally, the chimeric VLPs induced significantly higher IL-4 production in mice. These results demonstrate that chimeric VLPs have the potential for use in vaccines against IBV infection.
